A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia

A Double-Blind Dose-Response Study Comparing Rapid Acting Intramuscular Olanzapine and Intramuscular Placebo in Agitated Patients With Schizophrenia

To investigate dose-response of Rapid Acting Intramuscular Olanzapine in Agitated Patients with Schizophrenia

Inclusion Criteria:

• Patients must have schizophrenia that meets disease diagnostic criteria in DSM-IV-TR
• Patients must be inpatients during the study
• Patients must have a minimum total score of no less than 14 on the five items of the PANSS-EC and at least one individual item score of no less than 4 using the 1-7 scoring system prior to the first injection of study drug

Exclusion Criteria:

• Patients who have a known history of diabetes mellitus.
• Patients who have received treatment with antipsychotics or other prohibited concomitant medicines within 2 hours prior to the first IM study drug administration
• Patients who have had treatment with benzodiazepines within 4 hours prior to first IM study drug administration.